#vaccine research

Unlike custom-made vaccines, those that target common cancer antigens could be available off the shelf.

The experimental vaccine trains the immune system to recognize HER2 proteins on breast tumors.

Vaccines are tested for safety, but like all medical products, they can sometimes cause side effects.

NIAID-supported research sheds light on why healthy people of the same age respond differently to vaccines.

A personalized cancer vaccine plus Keytuda lowered the risk of melanoma coming back after surgery.

A single vaccine dose delivered to nose aims to protect children and adults against COVID.

NIH study finds therapeutic vaccine administered via IV infusion improves tumor-fighting T-cell action in mice.

EBV causes mononucleosis and certain cancers, and it may play a role in multiple sclerosis and long COVID.

Nearly all HIV-positive study participants achieved protective antibody levels after two doses of Heplisav-B.

A mathematical technique called matrix completion could speed up the development of vaccines for flu and COVID-19 variants.

The research is vital because Epstein-Barr virus is linked to cancers, lupus, rheumatoid arthritis, multiple sclerosis and other conditions.

Vaccines designed to produce a strong T cell response may help protect against current and future SARS-CoV-2 variants.

Over the past decade, the field of mRNA therapeutics has advanced rapidly.

A vaccine designed to enhance T-cell activity could help CAR-T therapy work better against solid tumors.

CoVac-1 induced T-cell responses in about 90% of immunocompromised people with impaired B-cell function.

The quick spread of the BA.2 subvariant is likely due to its greater infectiousness rather than its ability to evade the immune system.